Effects of two basidiomycete species on interleukin 1 and interleukin 2 production by macrophage and T cell lines

Immunobiology

Volumn 215, Issue 7, 2010, Pages 516-520

  Kawanishi, Takashi ^a,b,c   Ikeda Dantsuji, Yurika ^a   Nagayama, Ariaki ^a,c  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kobayashi Pharmaceutical Co   (Japan)

^c Fukuoka Tenjin Blood Center   (Japan)

Author keywords

Basidiomycete; Cytokine; Immuno stimulation; Macrophage; T cell

Indexed keywords

CORDYCEPS SINENSIS EXTRACT; FUNGAL EXTRACT; INTERLEUKIN 1; INTERLEUKIN 2; LENTINUS EDODES MYCELIA EXTRACT; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BASIDIOMYCETES; CANCER PATIENT; CELL LINE; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; IMMUNOCOMPROMISED PATIENT; IMMUNOSTIMULATION; LENTINUS EDODES MYCELIA; LYMPHOCYTE ACTIVATION; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; OPHIOCORDYCEPS; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; ANIMAL; C3H MOUSE; CORDYCEPS; IMMUNOLOGY; LENTINULA EDODES; METABOLISM; MICROBIOLOGY; PATHOLOGY; SECRETION (PROCESS);

ALLERGY AND IMMUNOLOGY; ANIMALS; CELL LINE; CORDYCEPS; DIETARY SUPPLEMENTS; INTERLEUKIN-1; INTERLEUKIN-2; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED C3H; PHYTOHEMAGGLUTININS; SHIITAKE MUSHROOMS; T-LYMPHOCYTES; TH1 CELLS;

EID: 77953611166     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2009.10.005     Document Type: Article

References (33)

1. Akaki J., Matsui Y., Kojima H., Nakajima S., Kamei K., Tamesada M. Structural analysis of monocyte activation constituents in cultured mycelia of Cordyceps sinensis. Fitoterapia 2009, 80:182-187.
2. Angell M., Kassirer J. Alternative medicine - the risks of untested and unregulated remedies. New. Eng. J. Med. 1998, 339:839-841.
3. Ehrke M.J. Immunomodulation in cancer therapeutics. Int. Immunopharmacol. 2003, 3:1105-1119.
4. Eynde B.J., Bruggen P. T cell defined tumor antigens. Curr. Opin. Immunol. 1997, 9:684-693.
5. Fujimiya Y., Suzuki Y., Oshiman K., Kobori H., Moriguchi K., Nakashima H. Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol. Immunother. 1998, 46:147-159.
6. Gillis S., Mizel.S.B. T-cell lymphoma model for the analysis of interleukin 1-mediated T-cell activation. Proc. Natl. Acad. Sci. USA 1981, 78:1133-1137.
7. Gillis S., Scheid M., Watson J. Biochemical and biologic characterization of lymphocyte regulatory molecules III. The isolation and phenotypic characterization of interleukin-2 producing T cell lymphomas. J. Immunol. 1980, 125:2570-2578.
8. Harris P., Ress R. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complement. Ther. Med. 2000, 8:88-96.
9. Hyodo I., Amano N., Eguchi K., Narabayashi M., Imanishi J., Hirai M. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J. Clin. Oncol. 2005, 23:2645-2654.
10. Itoh A., Isoda K., Kondoh M., Kawase M., Kobayashi M., Tamesada M., Yagi K. Hepatoprotective effect of syringic acid and vanillic acid on Concanavalin A-Induced liver injury. Biol. Pharm. Bull. 2009, 32:1215-1219.
11. Jaffee E.M., Pardoll D.M. Murine tumor antigens: is it worth the search?. Curr. Opin. Immunol. 1996, 8:622-627.
12. Kamla P.M., Lilly G., Sudipta C., Dev Karan, Ramesh C.S. Aqueous extract of Rhodiola imbricata rhizome stimulates Toll-like receptor 4, granzyme-B and Th1 cytokines in vitro. Immunobiology 2009, 214:27-31.
13. Kim J., Park E.J. Cytotoxic anticancer candidates from natural resources. Curr. Med. Chem. Anticancer Agents 2002, 2:485-537.
14. Kimura Y., Taniguchi M., Baba K. Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Aniticancer Res. 2002, 22:3309-3318.
15. Kraehenbuhl J.P., Neutra M.R. Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 2000, 16:301-332.
16. Melief C.J., Offringa R., Toes R.E., Kast W.M. Peptide-based cancer vaccines. Curr. Opin. Immunol. 1996, 8:651-657.
17. Mizoguchi Y., Katoh H., Kobayashi K., Yamamoto S., Morisawa S. Protection of liver cells against experimental damage by extract of cultured Lentinus edodes mycelia (LEM). Gastroenterol. Jpn. 1987, 22:459-464.
18. Mohammad-Fata M., Hossein M., Shirin G., Ghorban-Ali H. Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int. Immunopharmacol. 2007, 7:701-724.
19. Morse M.A., Chui S., Hobeika A., Lyerly H.K., Clay T. Recent developments in therapeutic cancer vaccines. Nat. Clin. Pract. Oncol. 2005, 2:108-113.
20. Nagashima Y., Sanpei N., Yamamoto S., Yoshino S., Tangoku A., Oka M. Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy). Jpn. J. Cancer Chemother. 2005, 32:1550-1552.
21. Nishimura T., Nakui M., Sato M., Iwakabe K., Kitamura H., Sekimoto M. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 2000, 46:S52-61.
22. Ohki K., Nagayama A. Properties of colony-stimulating factors produced by macrophage cell lines and hybrid cells. J. Cell. Physiol. 1987, 130:68-76.
23. Ohno N., Furukawa M., Miura N., Adachi Y., Motoi M., Yadomae T. Antitumor beta glucan from the cultured fruit body of Agaricus blazei. Biol. Pharm. Bull. 2001, 24:820-828.
24. Pardoll D. T cells and tumours. Nature 2001, 411:1010-1012.
25. Ridge J.P., Di, Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
26. Rimoldi M., Chieppa M., Larghi P., Vulucano M., Allavena P., Rescigno M. Monocyte-derived dendric cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally different. Blood 2005, 106:2818-2826.
27. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol. Today 1991, 12:256-257.
28. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Eng. J. Med. 1987, 316:889-897.
29. Soejima T., Nagayama A., Sado T., Taniguchi M. Acquisition of repertoires of suppressor T cells under the influence of macrophages. J. Mol. Cell Immunol. 1988, 4:87-95.
30. Sugano N., Hibino Y., Choji Y., Maeda H. Anticarcinogenic actions of water-soluble and alcohol-insoluble fractions from culture medium of Lentinus edodes mycelia. Cancer Lett. 1982, 17:109-114.
31. Tagawa M. Cytokine Therapy for Cancer. Curr. Pharm. Des. 2000, 6:681-699.
32. Tang J.L., Liu B.Y., Ma K.W. Traditional Chinese medicine. Lancet 2008, 372:1938-1940.
33. 3H/HeN cells by cell fusion. Nature 1981, 290:58-59.